Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
NCT ID: NCT06503848
Last Updated: 2024-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
108 participants
OBSERVATIONAL
2024-01-25
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache
NCT02485340
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
NCT04825678
Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks
NCT04948164
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
NCT02619617
Phase 3 Study of MAP0004 in Adult Migraineurs
NCT00623636
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are some interindividual differences in clinical characteristics of migraine attacks. These differences may determine the response to acute treatment. Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment.
The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan.
Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
episodic migraine
Patients with episodic migraine will be asked to treat four spontaneous migraine attacks with sumatriptan 50 milligrams. They will register the headache characteristics and whether or not the treatment was effective.
Sumatriptan
Register the response to treatment and headache characteristics.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sumatriptan
Register the response to treatment and headache characteristics.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \<8 migraine days per month
* Be able to read, write and understand instructions.
* Have internet access and mail address
* Signing of the informed consent
Exclusion Criteria
* Active medication with an effect over the central nervous system
* Serious physical or psychiatric condition
* Cardiovascular or hepatic disease
* Pregnant or breastfeeding women
* Any triptan contraindication
* Severe migraine attacks without previous response to triptans or NSAIDs
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto de Salud Carlos III
OTHER_GOV
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marta Torres-Ferrús, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitari Vall d'Hebron, Headache & Neurological Pain Research Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOM(AG)053/2022(6055)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.